Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors

Autor: Joseph-Philippe Etievent, Nicolas Meneveau, Frédéric Deschaseaux, Pierre-Emmanuel Falcoz, Nursen Mersin, Pierre Tiberghien, Zohair Selmani, Alfred Penfornis, Sidney Chocron, C. Kleinclauss, Jean-Pierre Kantelip, Siamak Davani
Přispěvatelé: Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( EA 3920) (PCVP / CARDIO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Diabétologie - Endocrinologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Saas, Philippe, Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920) (PCVP / CARDIO), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( PCVP / CARDIO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Service de diabétologie - endocrinologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz
Rok vydání: 2006
Předmět:
CD31
Male
CD34
MESH : Aged
MESH: Flow Cytometry
Antigens
CD34
Cell Count
Coronary Disease
030204 cardiovascular system & hematology
MESH : Cell Count
MESH: Cadherins
0302 clinical medicine
[ SDV.IMM ] Life Sciences [q-bio]/Immunology
MESH : Female
MESH: Endothelial Cells
MESH: Antigens
CD
Cells
Cultured
MESH: Aged
0303 health sciences
MESH: Middle Aged
Stem Cells
Middle Aged
Cadherins
Flow Cytometry
3. Good health
Endothelial stem cell
Platelet Endothelial Cell Adhesion Molecule-1
MESH: Leukocytes
Mononuclear
medicine.anatomical_structure
MESH : Antigens
CD31
MESH : Stem Cells
MESH : Antigens
CD34
[SDV.IMM]Life Sciences [q-bio]/Immunology
Female
MESH : Cadherins
Stem cell
MESH : Colony-Forming Units Assay
MESH: Cells
Cultured
MESH : Antigens
CD146
medicine.medical_specialty
[SDV.IMM] Life Sciences [q-bio]/Immunology
MESH : Flow Cytometry
MESH : Male
MESH : Vascular Endothelial Growth Factor Receptor-2
MESH: Stem Cells
CD146 Antigen
Biology
Endothelial progenitor cell
Colony-Forming Units Assay
03 medical and health sciences
Antigens
CD
Internal medicine
MESH : Cells
Cultured
MESH: Antigens
CD146
medicine
MESH : Antigens
CD
MESH: Colony-Forming Units Assay
Humans
MESH : Middle Aged
Progenitor cell
MESH: Hydroxymethylglutaryl-CoA Reductase Inhibitors
030304 developmental biology
Interleukin 3
Aged
Pharmacology
MESH: Humans
MESH: Vascular Endothelial Growth Factor Receptor-2
MESH : Endothelial Cells
MESH: Cell Count
MESH : Humans
MESH : Hydroxymethylglutaryl-CoA Reductase Inhibitors
Endothelial Cells
MESH: Antigens
CD31
MESH: Antigens
CD34
Vascular Endothelial Growth Factor Receptor-2
MESH: Male
MESH : Leukocytes
Mononuclear
Endocrinology
MESH : Coronary Disease
Leukocytes
Mononuclear
Bone marrow
MESH: Coronary Disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
MESH: Female
Zdroj: European Journal of Pharmacology
European Journal of Pharmacology, Elsevier, 2007, 562 (1-2), pp.111-8. ⟨10.1016/j.ejphar.2007.01.045⟩
European Journal of Pharmacology, Elsevier, 2007, 562 (1-2), pp.111-8. 〈10.1016/j.ejphar.2007.01.045〉
ISSN: 0014-2999
DOI: 10.1016/j.ejphar.2007.01.045⟩
Popis: International audience; 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used to decrease cholesterol synthesis and are well established to reduce vascular diseases. Recently, it has been proposed that statins mobilize endothelial progenitor cells from bone marrow during the first four weeks, which could help to prevent vascular diseases. However, in humans there are few data concerning the long term effects of statin treatment on these endothelial progenitor cells. We investigated whether endothelial progenitor cells can be detected and characterized in patients receiving long term statin therapy. Mononuclear cells from patients receiving or not receiving statin therapy were assessed for progenitor cell content by flow cytometry and were cultured in specific conditions to determine the number and the type of progenitors. Our results showed there were significantly more CD34(+), CD34(+)/CD144(+) circulating progenitor cells in the statin(pos) group than in the statin(neg) group. In culture two types of endothelial progenitor cells were detected. Early endothelial progenitor cells gave colonies at day 5 comprising elongated cells whereas late endothelial progenitor cells generated cobblestone-like colonies with strong proliferation capacities. The number of circulating early endothelial progenitor cells was significantly higher in the statin(neg) group, while only late endothelial progenitor cells were detected in the statin(pos) group. Moreover, cells from cobblestones clearly had an endothelial phenotype CD31(+), VEGF-R2(+), CD34(+), CD146(+) in contrast to cells from colonies from early endothelial progenitor cells, which were VEGF-R2(low), CD34(-). These results strongly suggest that long term statin treatment specifically maintains late endothelial progenitor cells in circulation with a CD34(+)/CD144(+) phenotype.
Databáze: OpenAIRE
Externí odkaz: